Literature DB >> 21274535

Contribution of the immune system to the chemotherapeutic response.

Alison M McDonnell1, Anna K Nowak, Richard A Lake.   

Abstract

The immune system plays an important role in the surveillance of neoplastic cells by eliminating them before they manifest as full-blown cancer. Despite this, tumors do develop in the presence of a functioning immune system. Conventional chemotherapy and its ability to directly kill tumor cells is one of the most effective weapons in the fight against cancer, however, increasing evidence suggests that the therapeutic efficacy of some cytotoxic drugs relies on their capacity to interact with the immune system. Killing of tumor cells in a manner that favors their capture by immune cells or selective targeting of immunosuppressive pathways by specific chemotherapies promotes the generation of an effective anti-cancer response; however, this alone is rarely sufficient to cause elimination of advanced disease. An understanding of the immunological events occurring in both animal models and patients undergoing chemotherapy will guide decisions for the development of appropriate combinations and scheduling for the integration of chemotherapy with immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21274535     DOI: 10.1007/s00281-011-0246-z

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   11.759


  137 in total

Review 1.  Immunological aspects of cancer chemotherapy.

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

2.  Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.

Authors:  Markus Loeffler; Jörg A Krüger; Ralph A Reisfeld
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

3.  Antitumor effects of kethoxal-bis(thiosemicarbazone) and 6-mercaptopurine in neonatally thymectomized mice.

Authors:  J F Ferrer; E Mihich
Journal:  Proc Soc Exp Biol Med       Date:  1967-03

4.  Calreticulin exposure dictates the immunogenicity of cancer cell death.

Authors:  Michel Obeid; Antoine Tesniere; François Ghiringhelli; Gian Maria Fimia; Lionel Apetoh; Jean-Luc Perfettini; Maria Castedo; Grégoire Mignot; Theoharis Panaretakis; Noelia Casares; Didier Métivier; Nathanael Larochette; Peter van Endert; Fabiola Ciccosanti; Mauro Piacentini; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Med       Date:  2006-12-24       Impact factor: 53.440

5.  A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation.

Authors:  E Zorn; T Hercend
Journal:  Eur J Immunol       Date:  1999-02       Impact factor: 5.532

6.  Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

Authors:  J B A G Haanen; A Baars; R Gomez; P Weder; M Smits; T D de Gruijl; B M E von Blomberg; E Bloemena; R J Scheper; S M van Ham; H M Pinedo; A J M van den Eertwegh
Journal:  Cancer Immunol Immunother       Date:  2005-07-21       Impact factor: 6.968

7.  Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.

Authors:  Galina V Shurin; Irina L Tourkova; Ramon Kaneno; Michael R Shurin
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

8.  Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.

Authors:  Markéta Tomsová; Bohuslav Melichar; Iva Sedláková; Ivo Steiner
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

9.  Uric acid promotes tumor immune rejection.

Authors:  De-En Hu; Alistair M Moore; Lindy L Thomsen; Kevin M Brindle
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

10.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

View more
  17 in total

Review 1.  Immunological off-target effects of standard treatments in gastrointestinal cancers.

Authors:  A G Duffy; T F Greten
Journal:  Ann Oncol       Date:  2013-11-07       Impact factor: 32.976

2.  Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer.

Authors:  F Aranda; N Bloy; J Pesquet; B Petit; K Chaba; A Sauvat; O Kepp; N Khadra; D Enot; C Pfirschke; M Pittet; L Zitvogel; G Kroemer; L Senovilla
Journal:  Oncogene       Date:  2014-07-28       Impact factor: 9.867

3.  Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer.

Authors:  Robert Wesolowski; Megan C Duggan; Andrew Stiff; Joseph Markowitz; Prashant Trikha; Kala M Levine; Lynn Schoenfield; Mahmoud Abdel-Rasoul; Rachel Layman; Bhuvaneswari Ramaswamy; Erin R Macrae; Maryam B Lustberg; Raquel E Reinbolt; Ewa Mrozek; John C Byrd; Michael A Caligiuri; Thomas A Mace; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2017-07-07       Impact factor: 6.968

Review 4.  Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy.

Authors:  C G Drake; P Sharma; W Gerritsen
Journal:  Oncogene       Date:  2013-11-25       Impact factor: 9.867

5.  Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy.

Authors:  Susan R Slovin
Journal:  Front Oncol       Date:  2012-05-30       Impact factor: 6.244

6.  Tumor Infiltrating Lymphocytes - The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer.

Authors:  Robert Wesolowski; William E Carson
Journal:  J Carcinog Mutagen       Date:  2014-12

Review 7.  Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies.

Authors:  Puneeth Iyengar; David E Gerber
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 2.074

8.  Restoration of defective cross-presentation in tumors by gemcitabine.

Authors:  Alison M McDonnell; W Joost Lesterhuis; Andrea Khong; Anna K Nowak; Richard A Lake; Andrew J Currie; Bruce Ws Robinson
Journal:  Oncoimmunology       Date:  2015-02-25       Impact factor: 8.110

9.  Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model.

Authors:  Jennifer S Dickey; Yanira Gonzalez; Baikuntha Aryal; Steven Mog; Asako J Nakamura; Christophe E Redon; Ulrich Baxa; Elliot Rosen; Gang Cheng; Jacek Zielonka; Palak Parekh; Karen P Mason; Joy Joseph; Balaraman Kalyanaraman; William Bonner; Eugene Herman; Emily Shacter; V Ashutosh Rao
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies.

Authors:  Alistair M Cook; Alison M McDonnell; Richard A Lake; Anna K Nowak
Journal:  Oncoimmunology       Date:  2015-09-16       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.